Literature DB >> 18784309

Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.

Nektaria Nicolakakis1, Tahar Aboulkassim, Brice Ongali, Clotilde Lecrux, Priscilla Fernandes, Pedro Rosa-Neto, Xin-Kang Tong, Edith Hamel.   

Abstract

Accumulating evidence suggests that cerebrovascular dysfunction is an important factor in the pathogenesis of Alzheimer's disease (AD). Using aged ( approximately 16 months) amyloid precursor protein (APP) transgenic mice that exhibit increased production of the amyloid-beta (Abeta) peptide and severe cerebrovascular and memory deficits, we examined the capacity of in vivo treatments with the antioxidants N-acetyl-L-cysteine (NAC) and tempol, or the peroxisome proliferator-activated receptor gamma agonist pioglitazone to rescue cerebrovascular function and selected markers of AD neuropathology. Additionally, we tested the ability of pioglitazone to normalize the impaired increases in cerebral blood flow (CBF) and glucose uptake (CGU) induced by whisker stimulation, and to reverse spatial memory deficits in the Morris water maze. All compounds fully restored cerebrovascular reactivity of isolated cerebral arteries concomitantly with changes in proteins regulating oxidative stress, without reducing brain Abeta levels or Abeta plaque load. Pioglitazone, but not NAC, significantly attenuated astroglial activation and improved, albeit nonsignificantly, the reduced cortical cholinergic innervation. Furthermore, pioglitazone completely normalized the CBF and CGU responses to increased neuronal activity, but it failed to improve spatial memory. Our results are the first to demonstrate that late pharmacological intervention with pioglitazone not only overcomes cerebrovascular dysfunction and altered neurometabolic coupling in aged APP mice, but also counteracts cerebral oxidative stress, glial activation, and, partly, cholinergic denervation. Although early or combined therapy may be warranted to improve cognition, these findings unequivocally point to pioglitazone as a most promising strategy for restoring cerebrovascular function and counteracting several AD markers detrimental to neuronal function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784309      PMCID: PMC6670922          DOI: 10.1523/JNEUROSCI.3348-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  118 in total

1.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

2.  Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Authors:  Michael Gold; Claire Alderton; Marina Zvartau-Hind; Sally Egginton; Ann M Saunders; Michael Irizarry; Suzanne Craft; Gary Landreth; Ulla Linnamägi; Sharon Sawchak
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-21       Impact factor: 2.959

Review 3.  Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease.

Authors:  Magali Dumont; Michael T Lin; M Flint Beal
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 4.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

5.  Therapy for Alzheimer's Disease: How Effective are Current Treatments?

Authors:  Krista L Lanctôt; Ryan D Rajaram; Nathan Herrmann
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

6.  Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model.

Authors:  Kalliopi Thanopoulou; Apostolia Fragkouli; Fotini Stylianopoulou; Spiros Georgopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-12       Impact factor: 11.205

7.  Nurr1 and PPARγ protect PC12 cells against MPP(+) toxicity: involvement of selective genes, anti-inflammatory, ROS generation, and antimitochondrial impairment.

Authors:  Mohammad Jodeiri Farshbaf; Mahboobeh Forouzanfar; Kamran Ghaedi; Abbas Kiani-Esfahani; Maryam Peymani; Alireza Shoaraye Nejati; Tayebeh Izadi; Khadijeh Karbalaie; Maryam Noorbakhshnia; Soheila Rahgozar; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani
Journal:  Mol Cell Biochem       Date:  2016-07-19       Impact factor: 3.396

8.  Catechin treatment improves cerebrovascular flow-mediated dilation and learning abilities in atherosclerotic mice.

Authors:  Annick Drouin; Virginie Bolduc; Nathalie Thorin-Trescases; Élisabeth Bélanger; Priscilla Fernandes; Edward Baraghis; Frédéric Lesage; Marc-Antoine Gillis; Louis Villeneuve; Edith Hamel; Guylaine Ferland; Eric Thorin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-24       Impact factor: 4.733

9.  Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.

Authors:  Luis Escribano; Ana-María Simón; Esther Gimeno; Mar Cuadrado-Tejedor; Rakel López de Maturana; Ana García-Osta; Ana Ricobaraza; Alberto Pérez-Mediavilla; Joaquín Del Río; Diana Frechilla
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

10.  Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition.

Authors:  Byung Hee Han; Meng-Liang Zhou; Fadi Abousaleh; Robert P Brendza; Hans H Dietrich; Jessica Koenigsknecht-Talboo; John R Cirrito; Eric Milner; David M Holtzman; Gregory J Zipfel
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.